Renovaro (NASDAQ:RENB - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.02) EPS for the quarter, Zacks reports.
Renovaro Trading Down 1.2 %
Renovaro stock traded down $0.01 during mid-day trading on Friday, hitting $0.84. The company had a trading volume of 329,651 shares, compared to its average volume of 1,008,320. Renovaro has a 12 month low of $0.40 and a 12 month high of $3.38. The company has a market capitalization of $132.85 million, a PE ratio of -0.91 and a beta of 0.63. The stock's 50 day moving average price is $0.92 and its two-hundred day moving average price is $0.76.
About Renovaro
(
Get Free Report)
Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.
Read More
Before you consider Renovaro, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Renovaro wasn't on the list.
While Renovaro currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
